These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8857548)

  • 41. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
    Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
    Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside.
    Masquelier M; Vitols S
    Biochem Pharmacol; 2004 May; 67(9):1639-46. PubMed ID: 15081863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
    Ozkaynak MF; Avramis VI; Carcich S; Ortega JA
    Med Pediatr Oncol; 1998 Dec; 31(6):475-82. PubMed ID: 9835899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
    Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF; Huang P; Plunkett W; Gandhi V
    Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
    [TBL] [Abstract][Full Text] [Related]  

  • 47. No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?
    Visani G; Isidori A; Grafone T; Tosi P; Santini V; Malagola M; Martinelli G; Piccaluga PP; Gaziev D; Ottaviani E; Sparaventi G; Tura S
    Leuk Lymphoma; 2004 Jul; 45(7):1361-4. PubMed ID: 15359633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.
    Hiddemann W
    Ann Hematol; 1991 Apr; 62(4):119-28. PubMed ID: 2031974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclopentenyl cytosine induces apoptosis and increases cytarabine-induced apoptosis in a T-lymphoblastic leukemic cell-line.
    Verschuur AC; Brinkman J; Van Gennip AH; Leen R; Vet RJ; Evers LM; Voûte PA; Van Kuilenburg AB
    Leuk Res; 2001 Oct; 25(10):891-900. PubMed ID: 11532523
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two simple high-performance liquid chromatographic methods for simultaneous determination of 2'-deoxycytidine 5'-triphosphate and cytosine arabinoside 5'-triphosphate concentrations in biological samples.
    Danks MK
    J Chromatogr; 1982 Dec; 233():141-8. PubMed ID: 7161328
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A radioimmunoassay for cytosine arabinoside.
    Piall EM; Aherne GW; Marks VM
    Br J Cancer; 1979 Oct; 40(4):548-56. PubMed ID: 574019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ion-pair liquid chromatography of cytarabine and uracil-arabinoside in human plasma.
    Burk M; Volmer M; Fartash K; Schneider W
    Arzneimittelforschung; 1995 May; 45(5):616-9. PubMed ID: 7612064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells.
    Veuger MJ; Heemskerk MH; Honders MW; Willemze R; Barge RM
    Blood; 2002 Feb; 99(4):1373-80. PubMed ID: 11830489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein.
    Gati WP; Paterson AR; Larratt LM; Turner AR; Belch AR
    Blood; 1997 Jul; 90(1):346-53. PubMed ID: 9207471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients.
    Yoshida T; Kobayashi K; Okabe Y; Okumura H; Matano S; Kanno M; Takeda Y; Ohtake S; Nakamura S; Matuda T
    J Clin Pharmacol; 1994 Jan; 34(1):52-9. PubMed ID: 8132852
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
    Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
    Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
    Tavernier E; Le QH; Elhamri M; Thomas X
    Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia.
    Veuger MJ; Honders MW; Willemze R; Barge RM
    Eur J Haematol; 2002 Sep; 69(3):171-8. PubMed ID: 12406011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.